Cancer Research and Treatment

Original Articles

Gynecologic cancer

Safety and Tolerability of Weekly Genexol-PM, a Cremophor-Free Polymeric Micelle Formulation of Paclitaxel, with Carboplatin in Gynecologic Cancer: A Phase I Study: So Hyun Nam, Shin-Wha Lee, Young-Jae Lee, Yong Man Kim; Cancer Res Treat. 2023;55(4):1346-1354. Published online May 15, 2023; DOI: https://doi.org/10.4143/crt.2022.1436

Abstract PDF Supplementary Material PubReader ePub

Purpose
This phase I study was conducted to determine the maximum tolerated dose and the recommended phase II dose of weekly administered Genexol-PM combined with carboplatin in patients with gynecologic cancer.
Materials and Methods
This open-label, phase I, dose-escalation study of weekly Genexol-PM included 18 patients with gynecologic cancer, who were equally divided into three cohorts of dose levels. Cohort 1 received 100 mg/m² Genexol-PM and 5 area under the curve (AUC) carboplatin, cohort 2 received 120 mg/m² Genexol-PM and 5 AUC carboplatin, and cohort 3 received 120 mg/m² Genexol-PM and 6 AUC carboplatin. The safety and efficacy of each dose were analyzed for each cohort.
Results
Of the 18 patients, 11 patients were newly diagnosed and seven patients were recurrent cases. No dose-limiting toxicity was observed. The maximum tolerated dose was not defined, but a dose up to 120 mg/m² of Genexol-PM in combination with AUC 5-6 of carboplatin could be recommended for a phase II study. In this intention-to-treat population, five patients dropped out of the study (carboplatin-related hypersensitivity, n=1; refusal of consent, n=4). Most patients (88.9%) with adverse events recovered without sequelae, and no treatment-related death occurred. The overall response rate of weekly Genexol-PM in combination with carboplatin was 72.2%.
Conclusion
Weekly administered Genexol-PM with carboplatin demonstrated an acceptable safety profile in gynecologic cancer pati-ents. The recommended phase II dose of weekly Genexol-PM is up to 120 mg/m² when combined with carboplatin.

Citations

Citations to this article as recorded by

Multicore, SDS-Based Polyelectrolyte Nanocapsules as Novel Nanocarriers for Paclitaxel to Reduce Cardiotoxicity by Protecting the Mitochondria
Marzena Szwed, Anastazja Poczta-Krawczyk, Katarzyna D. Kania, Kacper Wiktorowski, Kamila Podsiadło, Agnieszka Marczak, Krzysztof Szczepanowicz
International Journal of Molecular Sciences.2025; 26(3): 901. CrossRef
Potent therapeutic efficacy of intranasally deliverable paclitaxel modified with pH-sensitive and PEGylated polymeric micelle against glioblastoma
Young-Beom Kim, Soo-Hwan Lee, Dayananda Kasala, Yuebin Zhao, Ao Jiao, JinWoo Hong, Jin Su Kim, A-Rum Yoon, Chae-Ok Yun
Journal of Controlled Release.2025; 382: 113711. CrossRef
Nanomaterials-driven in situ vaccination: a novel frontier in tumor immunotherapy
Naimeng Liu, Xiangyu Wang, Zhongzhao Wang, Yonemori Kan, Yi Fang, Jidong Gao, Xiangyi Kong, Jing Wang
Journal of Hematology & Oncology.2025;[Epub] CrossRef
Advances in the use of nanomicelles to enhance the efficacy of antitumour substances (review)
E. V. Sanarova, L. L. Nikolaeva, S. D. Shceglov, Zh. M. Kozlova, O. L. Orlova, N. A. Oborotova, A. V. Lantsova
Drug development & registration.2025;[Epub] CrossRef
Current insights into polymeric micelles for nasal drug delivery
Bence Sipos, Fatima Rajab, Gábor Katona, Ildikó Csóka
Expert Opinion on Drug Delivery.2025; : 1. CrossRef
Rational design of paclitaxel prodrugs for facile preparation of in-situ therapeutic system in antitumor applications
Lanqing Wang, Zhaofan Yang, Guanyu Jin, Bingzheng Yu, Wei Zhang, Xuesi Chen, Haochen Yao, Cuiping Yao, Shixian Lv
Chemical Engineering Journal.2025; : 164599. CrossRef
Redox-responsive polymer micelles co-encapsulating immune checkpoint inhibitors and chemotherapeutic agents for glioblastoma therapy
Zhiqi Zhang, Xiaoxuan Xu, Jiawei Du, Xin Chen, Yonger Xue, Jianqiong Zhang, Xue Yang, Xiaoyuan Chen, Jinbing Xie, Shenghong Ju
Nature Communications.2024;[Epub] CrossRef
Therapeutic impacts of GNE‑477‑loaded H2O2 stimulus‑responsive dodecanoic acid‑phenylborate ester‑dextran polymeric micelles on osteosarcoma
Songmu Pan, Zhuan Zou, Xiaofeng Zhou, Jiyong Wei, Huijiang Liu, Zhongyi Su, Gui Liao, Guangyu Huang, Zonggui Huang, Yi Xu, Minan Lu, Ronghe Gu
International Journal of Molecular Medicine.2024;[Epub] CrossRef
Functionalized Polymeric Micelles for Targeted Cancer Therapy: Steps from Conceptualization to Clinical Trials
Ana Serras, Célia Faustino, Lídia Pinheiro
Pharmaceutics.2024; 16(8): 1047. CrossRef
Simplified Gambogic Acid Prodrug Nanoparticles to Improve Efficiency and Reduce Toxicity for Clinical Translation Potential
Ruyi Wang, Yuxiao Xiao, Zhongtao Zhang, Xiaoxian Huang, Wanfang Zhu, Xiao Ma, Feng Feng, Wenyuan Liu, Lingfei Han, Wei Qu
Advanced Healthcare Materials.2024;[Epub] CrossRef

3,645 View
192 Download
8 Web of Science
10 Crossref

Second Primary Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancers after Breast Cancer Diagnosis: Korea Central Cancer Registry: Hyeong In Ha, Eun-Gyeong Lee, Jiwon Lim, So-Youn Jung, Yoon Jung Chang, Young-Joo Won, Myong Cheol Lim; Cancer Res Treat. 2021;53(2):541-548. Published online November 18, 2020; DOI: https://doi.org/10.4143/crt.2020.1001

Abstract PDF PubReader ePub

Purpose
A prior history of breast cancer is a risk factor for the subsequent development of primary peritoneal, epithelial ovarian, and fallopian tubal (POFT) cancers. This study aimed to estimate the incidence of secondary POFT malignancy in breast cancer patients and the clinical outcomes of primary and secondary POFT cancer.
Materials and Methods
We searched the Korea Central Cancer Registry to find patients with primary and secondary POFT cancer who had breast cancer in 1999-2017. The incidence rate and standardized incidence ratio were calculated. Additionally, we compared the overall survival of patients with primary and secondary POFT cancer.
Results
Based on the age-standardized rate, the incidence of second primary POFT cancer after breast cancer was 0.0763 per 100,000 women, which increased in Korea between 1999 and 2017. Among the 30,366 POFT cancer patients, 25,721 were primary POFT cancer only, and 493 had secondary POFT cancer after a breast cancer diagnosis. Second primary POFT cancer patients were older at the time of diagnosis (55 vs. 53, p < 0.001) and had a larger proportion of serous histology (68.4% vs. 51.2%, p < 0.001) than patients with primary POFT. There were no differences between the two groups in tumor stage at diagnosis. The 5-year overall survival rates were 60.2% and 56.3% for primary and secondary POFT cancer, respectively (p=0.216).
Conclusion
The incidence of second primary POFT cancer after breast cancer increased in Korea between 1999 and 2017. Besides, second primary POFT cancer patients were diagnosed at older ages and had more serous histology.

Citations

Citations to this article as recorded by

Das Ovarialkarzinom: Score-Werte zur Definition von Risikopatientinnen
Eberhard Paul, Sebastian M. Jud
Geburtshilfe und Frauenheilkunde.2024; 84(03): 226. CrossRef
Risk for Second Primary Ovarian Cancer: A Large Population Based on Surveillance, Epidemiology, and End Results Database
Haiyang Hu, Yangsheng Ren, Huixing Li, Tishuo Zhang, Lin Sun
Oncology.2024; : 1. CrossRef
High-grade pelvic-type serous carcinoma presenting as a breast rash
Mark Weingarten, Michael Weingarten, Tamara Kalir, Angela Lamb
JAAD Case Reports.2022; 20: 20. CrossRef

6,345 View
141 Download
1 Web of Science
3 Crossref

First
Prev
Page of 1
Next
Last

Search